Alpheus Medical is a private, clinical-stage oncology company developing a groundbreaking, non-invasive treatment for solid tumors utilizing sonodynamic therapy (SDT). Its proprietary platform combines Low-Intensity Diffuse Ultrasound (LIDU™) with oral 5-aminolevulinic acid (5-ALA), a sensitizing agent that selectively accumulates in tumor cells. This targeted approach aims to destroy cancer cells while sparing healthy tissue. Alpheus collaborates with global leaders in neuro-oncology and is supported by top healthcare investors and the venture vehicles of nonprofit organizations focused on cancer.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
05/16/25	$52,000,000	Series B	Action Potential Venture Capital Brightedge HealthQuest Capital OrbiMed Advisors Samsara BioCapital Sontag Innovation Fund The Brain Tumor Investment Fund	undisclosed